文献速递肿瘤 PET/CT核素与放射性配体治疗

前列腺癌分子影像与诊疗一体化:多学科协作路径

Molecular Imaging and Theranostics-A Multidisciplinary Approach.
PubMed 文献 · Semin Nucl Med · 2019-03-02

本文为综述,阐述前列腺癌因诊断、影像与治疗进展而管理日趋复杂,需多学科协作。分子影像在分期、生化复发再分期及去势抵抗阶段起关键决策作用;前列腺特异性膜抗原PET成像成为筛选靶向α或β核素治疗的「守门人」,推动诊疗一体化。

要点

  • 前列腺癌管理需多学科协作,分子影像在多数临床场景中起关键决策作用。
  • 前列腺特异性膜抗原PET成像用于筛选适合靶向α或β核素治疗的患者。
  • 放射性配体治疗自1946年首次临床应用,近年多种前列腺特异性膜抗原标记α或β核素被提出。

核心结论

  • 分子影像在前列腺癌决策中作用增强,前列腺特异性膜抗原PET成像成为通向靶向核素治疗的守门人。
  • 诊疗一体化在前列腺癌领域快速发展,使核医学处于中心地位,但需进一步前瞻性研究确认。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 分子影像在前列腺癌分期、生化复发再分期及去势抵抗阶段起关键作用。
  • 前列腺特异性膜抗原PET成像将患者导向正确治疗选择,并在晚期筛选适合靶向α或β核素治疗者。
  • 近年提出多种前列腺特异性膜抗原标记的α或β核素用于靶向治疗,适用于其他治疗对生存无显著影响者。

临床怎么用

  • 在前列腺癌分期、生化复发再分期和去势抵抗阶段,将分子影像纳入多学科决策。
  • 用前列腺特异性膜抗原PET成像作为守门人,筛选适合靶向α或β核素治疗的患者。

局限性

  • 诊疗一体化在前列腺癌中的中心作用尚需进一步前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer is a major global health care challenge. Due to the recent relevant improvements in the diagnosis, imaging and treatment, management of these patients is becoming extremely complex. However, new multiple diagnostic procedures and treatment options, tailored on the single patient, require a multidisciplinary effort. Molecular imaging is gaining importance in the decision making process of prostate cancer patients, playing a key role in the majority of clinical setting, including staging, restaging during biochemical recurrence and castration-resistant stage. Moreover recent significant advances are changing the management of these patients impacting on the choice of therapeutic strategy. In particular, prostate-specific membrane antigen PET imaging is assuming the role of the gatekeeper addressing patients to the correct treatment option and also, in the advanced stages, selecting patients potentially suitable for targeted α- or β-therapy bridging to the fascinating concept of theranostic. Even if radioligand therapy found its first clinical application in 1946, in the last few years several α- or β-radionuclide prostate-specific membrane antigen-labeled for targeted therapy have been proposed where other treatment options do not show a significant impact on survival. The theranostic field is experiencing a rapid growth in prostate cancer giving to nuclear medicine a central role that has to be confirmed by further prospective studies.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Farolfi A, Lima GM, Oyen W, et al. Molecular Imaging and Theranostics-A Multidisciplinary Approach. Semin Nucl Med. 2019. PMID: 31227048. doi:10.1053/j.semnuclmed.2019.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。